Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00718601 · ClinicalTrials.gov registry record · Phase 1
Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Geron Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT00718601 is a Phase 1 study of Multiple Myeloma that has completed, run by Geron Corporation. The registered enrollment target is 40 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00718601, a Phase 1 study of Multiple Myeloma, has completed, sponsored by Geron Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine safety and the maximum tolerated dose (MTD) of GRN163L and Velcade with and without Decadron when administered to patients with refractory or relapsed multiple myeloma.
Conditions Studied
Interventions
- DRUG Imetelstat Sodium (GRN163L)
Study Locations (3)
Michigan
- Karmanos Cancer Center - Detroit
New York
- St. Vincent's Comprehensive Cancer Center - New York
Washington
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00718601
The ClinicalTrials.gov registry entry for NCT00718601 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The listed sponsor is Geron Corporation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Imetelstat Sodium (GRN163L) is the first listed.
NCT00718601 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Michigan, New York, Washington.
Frequently Asked Questions
What is clinical trial NCT00718601 about?
NCT00718601 is a clinical study titled "Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma". The purpose of this study is to determine safety and the maximum tolerated dose (MTD) of GRN163L and Velcade with and without Decadron when administered to patients with refractory or relapsed multiple myeloma.
What is the current status of trial NCT00718601?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2008-07. Estimated completion is 2011-10.
What conditions does trial NCT00718601 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00718601?
The interventions under investigation include: Imetelstat Sodium (GRN163L) (DRUG).
Who is sponsoring clinical trial NCT00718601?
This trial is sponsored by Geron Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00718601 being conducted?
This trial has 3 study locations across Michigan, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.